MyoGene: Effects of Acute Exercise on (Myokine) Gene Expression in Human Skeletal Muscle
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Rationale: Proteins released from muscle during and shortly after exercise, often referred to as myokines, may be central to our understanding of the cross-talk during and after exercise between skeletal muscles and other organs, in particular the liver. So far only a few myokines are identified (e.g. IL-6, IL-8, IL-15, TNF-alpha). Taking into account the role of these several known myokines in developing insulin resistance, revealing new putative myokines might provide valuable information and a direction for future research on the pathogenesis and treatment of type 2 diabetes mellitus.
Objective: The objective of the present study is to identify novel myokines, expression of which is altered in skeletal muscle after a single bout of exercise.
Study design: experimental study. Study population: Ten healthy, male subjects between 40 and 60 years of age and BMI < 30 kg/m2, will participate in this study.
Intervention: A single exercise bout that consists of one hour one-legged cycling on a adapted recumbent cycle ergometer at a submaximal rate. The non-exercising leg will serve as control for the exercising leg.
Main study outcomes: Main study outcomes include upregulation of genes in skeletal muscle after exercise (with a focus on genes encoding myokines) and changes of blood plasma levels of selected proteins after exercise.
| Condition | Intervention |
|---|---|
|
Exercise Muscle Gene Expression Myokine |
Other: Single legged exercise |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Basic Science |
| Official Title: | Effects of Acute Exercise on (Myokine) Gene Expression in Human Skeletal Muscle |
- Gene expression changes in skeletal muscle from baseline to after exercise [ Time Frame: T = 0 and T =1 ] [ Designated as safety issue: No ]Gene expression is measured using whole genome Affymatrix microarrays Muscle tissue will be collected at time points T = 0 (before exercise) and T = 1 (directly after exercise). Special focus is on the changes in genes coding for myokines. Up to 5 genes will be selected for follow-up analysis.
- Changes in plasma levels of selected proteins [ Time Frame: T = 0, T =1 and T = 3 ] [ Designated as safety issue: No ]Selected proteins will be analyzed by ELISA assays or western blot analysis, depending on ELISA availability at T = 0, T = 1 and T = 3 (2 hours post-exercise). The selection of the proteins is based on significance, the robustness of induction (>80% of subjects showing induction) and the magnitude of the induction ( mean fold change > 2)
- PBMC gene expression changes before and after exercise [ Time Frame: T = 0, T = 1 and T =3 ] [ Designated as safety issue: No ]Gene expression changes in the blood will be assessed using whole genome Affymetrix microarrays for the samples at T = 0, 1 and 3.
- Routine plasma level changes before and after exercise [ Time Frame: T = 0, 1 and 3 ] [ Designated as safety issue: No ]At all three time point (T = 0, 1 and 3) plasma levels of glucose, insulin, fatty acids, triglycerides, cortisol, adrenalin and lactate will be determined.
- Heart rate changes, baseline compared with exercise [ Time Frame: During the intervention ] [ Designated as safety issue: No ]Heart rate will be measured during the maximum work load test and the experimental exercise period.
| Enrollment: | 12 |
| Study Start Date: | February 2011 |
| Study Completion Date: | June 2011 |
| Primary Completion Date: | June 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Exercise |
Other: Single legged exercise
A single exercise bout that consists of one hour one-legged cycling on a adapted recumbent cycle ergometer at a submaximal rate. The non-exercising leg will serve as control for the exercising leg.
|
Eligibility| Ages Eligible for Study: | 40 Years to 60 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Age 40-60 years
- Male gender
- BMI < 30 kg/m2
Exclusion Criteria:
- Exercising regularly (> 2 times a week, > 3 hour in total per week)
- Unstable body weight (weight gain or loss > 3 kg in the past three months)
- Following, or have recently followed a (weight-loss) diet
- Donated or intended to donate blood 2 months before until two months after the study
- Medical condition that can interfere with the study outcome (i.e. cardiovascular disease, pulmonary disease)
- Systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg
- Use of medications known to interfere with gene expression in the muscles (i.e. statins, fenofibrate).
- Use of antithrombotic therapy (marcoumar, sintromitis).
- Diagnosed diabetes mellitus type 1 or 2.
- Drugs or alcohol abuse ( > 3 glasses of alcoholic beverages a day).
- (Chronic) injuries of the locomotor system that can interfere with the intervention
- Participated in another study within the last six months
Contacts and Locations More Information
No publications provided
| Responsible Party: | Wageningen University |
| ClinicalTrials.gov Identifier: | NCT01316731 History of Changes |
| Other Study ID Numbers: | NL33968.081.10 |
| Study First Received: | March 10, 2011 |
| Last Updated: | December 20, 2011 |
| Health Authority: | Netherlands: Medical Ethics Review Committee (METC) |
ClinicalTrials.gov processed this record on May 19, 2013